In three consecutive articles published in On The Risk throughout 2025, Munich Re Life documented the effectiveness of EHR data in more than 800 underwriting cases across multiple carriers and every major evidence scenario. It’s the most comprehensive independent validation to date—and the findings are clear: EHR data reduces underwriting time and cost.
In Part 1 of this series, we covered the three forces that have made EHR data viable for insurance: regulatory enforcement, national exchange infrastructure, and modern interoperability standards. The access problem is largely solved. But access was never really the...
In a rapidly evolving healthcare data landscape, we explore EHR trends for underwriters and why these developments finally make EHR evidence underwriting-grade. For more than a decade Electronic Health Records (EHRs) have promised to improve efficiency in life insurance underwriting....
IWQOL-Lite-CT© (Impact of Weight on Quality of Life-Lite-Clinical Trials) is the gold standard patient-reported outcome (PRO) measure of weight-related quality of life in adults designed for use in clinical trials. As the exclusive licensor of IWQOL-Lite-CT©, Greenlight works with CROs and biopharma organizations to implement the measure for regulated clinical trials.
Clinical trial sponsors are constantly seeking ways to accelerate study timelines, thereby more rapidly delivering therapeutics to patients and optimizing return on R&D investment. Accelerating clinical trials means acquiring high-quality data faster. It means developing protocols, configuring technology, activating research...
Biometric data is a powerful addition to a study protocol, offering a variety of data about participants’ activity levels and well-being. Pattern has deep experience working with study teams to select the best-fit devices for their studies and integrating…
As the year comes to a close, the Pattern Health team has taken some time to reflect. We are honored to support you, our amazing partners, who are pushing the boundaries of research and developing life-changing therapeutics. This holiday season,...
With the expanding market of biometric devices, selecting the right tools for research studies can be challenging. In this article, we provide guidance to healthcare researchers on selecting biometric devices, considering factors such as cost, provisioning process, battery life, user experience, device family, accuracy, and reliability.
The U.S. Food and Drug Administration (FDA) recently released its long-awaited draft guidance supporting the use of decentralized clinical trials (DCTs) for drugs, biologics, and devices. The new guidance clarifies the FDA's position on DCTs, inspiring confidence in their use...
The Duke Clinical Research Institute study was the first to incorporate mobile health technology to follow heart failure patients long-term. The study showed that using patients’ biometric information and medication adherence data can help customize guideline-based recommendations to improve self-care....
When working with researchers and clinicians to design trials that include digital elements, it's important to speak the same language. Just as clinical lingo must be precise so that everyone understands its meaning, adding digital elements to a clinical trial...
A Moment with Madalina Sucala is part of our interview series featuring thought leaders in research and healthcare. Each interview includes 7 short and stimulating questions. Madalina Sucala, PhD, MBA is a behavioral scientist and digital health strategist with over 10...
